Sydbank A/S

  • ISIN: DK0010311471
  • Land: .

Nachricht vom 18.04.2017 | 09:31

Sydbank share buyback programme: transactions in week 15

Sydbank A/S / Miscellaneous

18-Apr-2017 / 09:31 CET/CEST
Dissemination of a Regulatory Announcement, transmitted by EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Aabenraa, Denmark, 2017-04-18 09:30 CEST (GLOBE NEWSWIRE) --

On 1 March 2017 Sydbank announced a share buyback programme of DKK 664m. The share buyback commenced on 2 March 2017 and will be completed by 31 December 2017.

The purpose of the share buyback programme is to reduce the share capital of Sydbank and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules.

The following transactions have been made under the share buyback programme:

  Number of shares     VWAP       Gross value (DKK)    
Accumulated, most recent announcement       426,000           
10 April 2017  
11 April 2017
12 April 2017
17,000 16,000 20,000
243.05 241.23 238.78
4,131,850.00 3,859,680.00 4,775,600.00
Total over week 15     53,000   12,767,130.00
Total accumulated during the share buyback programme   479,000      


All transactions were made under ISIN DK 0010311471 and effected by Danske Bank A/S on behalf of Sydbank A/S.

Further information about the transactions, cf Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council on market abuse and the Commission delegated regulation, is available in the attachment.

Following the above transactions, Sydbank holds a total of 3,164,041 own shares, equal to 4.38% of the Bank’s share capital.

Click on, or paste the following link into your web browser, to view the associated documents

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

News im Fokus

BASF SE: Ergebnis steigt im Geschäftsjahr 2017 deutlich und übertrifft Analystenschätzungen erheblich

18. Januar 2018, 16:49

Aktuelle Research-Studie

Original-Research: PHARMING (von First Berlin Equity Research GmbH): BUY PHARMING

18. Januar 2018